SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: backman who wrote (11831)6/4/2003 10:38:34 AM
From: Bucky Katt  Read Replies (1) | Respond to of 48461
 
OXGN--bingo big time, nice idea!>
stockcharts.com[h,a]daclyiay[pb50!b200!f][vc60][iUb14!La12,26,9]&pref=G

OXiGENE's lead cancer agent is granted FDA fast track (OXGN) 3.94: Announces that the FDA has granted "fast track" designation to co's lead tumor-starving compound, Combretastatin A4 Prodrug (CA4P), for the treatment of advanced anaplastic thyroid cancer.. CA4P currently is being evaluated in a Phase II study of patients with this disease.



To: backman who wrote (11831)6/9/2003 12:34:57 PM
From: Bucky Katt  Read Replies (1) | Respond to of 48461
 
OXGN, Bingo again! What is that, $2.40 to a high today of $19??

Holy Mackeral..........An 800% turn.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News